Rheoxtech

Rheoxtech is a private, preclinical-stage biotech leveraging microfluidic engineering to pioneer next-generation drug delivery solutions. The company's core technology enables the precise fabrication of advanced drug carriers, such as nanoparticles and microparticles, with controlled properties for enhanced therapeutic performance. Operating in the high-growth drug delivery and medical device sectors, Rheoxtech targets partnerships with pharmaceutical companies to reformulate existing drugs and develop novel delivery approaches for biologics and small molecules. As a pre-revenue platform company, its success hinges on validating its technology through preclinical studies and securing strategic collaborations or funding to advance programs toward clinical development.

Proprietary microfluidic technology for the precise fabrication of advanced drug carriers (e.g., nanoparticles, microparticles) with controlled size, composition, and drug release properties.

Rheoxtech competes in a crowded field with large CDMOs (Catalent, Lonza), specialty drug delivery companies (Ascendia Pharma, Pacira BioSciences), and numerous startups developing microfluidic and nanoparticle platforms. Differentiation requires demonstrating superior formulation control, scalability, and tangible preclinical efficacy advantages.